Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer

Shiu Dong Chung, Shih Ping Liu, Herng Ching Lin, Li Hsuan Wang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset. Methods: We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received treatment with GnRH agonists. We individually traced each PC patient for a 1-year period to identify those who were hospitalized with pneumonia. We performed a Cox proportional hazard regression to explore the association between the use of GnRH agonists and the risk of pneumonia during the 1-year follow-up period. Results: Incidence rates of pneumonia during the 1-year follow-up period were 4.35 (95% confidence interval (CI): 1.89-9.64) per 100 person-years and 2.14 (95% CI: 1.31-3.32) per 100 person-years for PC patients who did and those who did not receive treatment with GnRH agonists, respectively. The log-rank test suggested that there was a significant difference in the 1-year pneumonia-free survival rate between PC patients who did and those who did not receive treatment with GnRH agonists (p

Original languageEnglish
Article numbere101254
JournalPLoS One
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 27 2014

Fingerprint

hormone agonists
prostatic neoplasms
gonadotropin-releasing hormone
Gonadotropin-Releasing Hormone
pneumonia
Prostatic Neoplasms
Pneumonia
confidence interval
Health insurance
Confidence Intervals
health insurance
Health Insurance
Hazards
Taiwan
Therapeutics
Survival Rate
survival rate
Databases
incidence
Incidence

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer. / Chung, Shiu Dong; Liu, Shih Ping; Lin, Herng Ching; Wang, Li Hsuan.

In: PLoS One, Vol. 9, No. 6, e101254, 27.06.2014.

Research output: Contribution to journalArticle

@article{3682622ffc4048a8a9c9e10f0753ee69,
title = "Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer",
abstract = "Background: This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset. Methods: We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received treatment with GnRH agonists. We individually traced each PC patient for a 1-year period to identify those who were hospitalized with pneumonia. We performed a Cox proportional hazard regression to explore the association between the use of GnRH agonists and the risk of pneumonia during the 1-year follow-up period. Results: Incidence rates of pneumonia during the 1-year follow-up period were 4.35 (95{\%} confidence interval (CI): 1.89-9.64) per 100 person-years and 2.14 (95{\%} CI: 1.31-3.32) per 100 person-years for PC patients who did and those who did not receive treatment with GnRH agonists, respectively. The log-rank test suggested that there was a significant difference in the 1-year pneumonia-free survival rate between PC patients who did and those who did not receive treatment with GnRH agonists (p",
author = "Chung, {Shiu Dong} and Liu, {Shih Ping} and Lin, {Herng Ching} and Wang, {Li Hsuan}",
year = "2014",
month = "6",
day = "27",
doi = "10.1371/journal.pone.0101254",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer

AU - Chung, Shiu Dong

AU - Liu, Shih Ping

AU - Lin, Herng Ching

AU - Wang, Li Hsuan

PY - 2014/6/27

Y1 - 2014/6/27

N2 - Background: This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset. Methods: We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received treatment with GnRH agonists. We individually traced each PC patient for a 1-year period to identify those who were hospitalized with pneumonia. We performed a Cox proportional hazard regression to explore the association between the use of GnRH agonists and the risk of pneumonia during the 1-year follow-up period. Results: Incidence rates of pneumonia during the 1-year follow-up period were 4.35 (95% confidence interval (CI): 1.89-9.64) per 100 person-years and 2.14 (95% CI: 1.31-3.32) per 100 person-years for PC patients who did and those who did not receive treatment with GnRH agonists, respectively. The log-rank test suggested that there was a significant difference in the 1-year pneumonia-free survival rate between PC patients who did and those who did not receive treatment with GnRH agonists (p

AB - Background: This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset. Methods: We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received treatment with GnRH agonists. We individually traced each PC patient for a 1-year period to identify those who were hospitalized with pneumonia. We performed a Cox proportional hazard regression to explore the association between the use of GnRH agonists and the risk of pneumonia during the 1-year follow-up period. Results: Incidence rates of pneumonia during the 1-year follow-up period were 4.35 (95% confidence interval (CI): 1.89-9.64) per 100 person-years and 2.14 (95% CI: 1.31-3.32) per 100 person-years for PC patients who did and those who did not receive treatment with GnRH agonists, respectively. The log-rank test suggested that there was a significant difference in the 1-year pneumonia-free survival rate between PC patients who did and those who did not receive treatment with GnRH agonists (p

UR - http://www.scopus.com/inward/record.url?scp=84903388898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903388898&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0101254

DO - 10.1371/journal.pone.0101254

M3 - Article

C2 - 24971988

AN - SCOPUS:84903388898

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e101254

ER -